Coronary artery stenting in active duty soldiers

D Ebersole1, L Miller, S R Bailey

  • 1Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, Texas 78234-6262, USA.

Insights

Palmaz-Schatz coronary stenting shows promising results for active duty soldiers with coronary artery disease, demonstrating high angiographic success and low restenosis rates. This intervention may offer a valuable long-term treatment option for this population.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Vascular Surgery

Background:

  • Coronary artery disease (CAD) treatment in young patients requires consideration of long-term outcomes and potential repeat interventions.
  • Palmaz-Schatz coronary stents can reduce restenosis but carry risks of bleeding and vascular complications.

Purpose of the Study:

  • To evaluate the efficacy and safety of intracoronary stenting using Palmaz-Schatz stents in young active duty soldiers with CAD.

Main Methods:

  • A cohort of fifteen active duty soldiers (age 37-53) underwent elective Palmaz-Schatz stent placement between March 1988 and December 1994.
  • Assessed for angiographic success, complications, and 6-month angiographic follow-up.
  • Monitored clinical outcomes up to a mean of 33 months post-procedure.

Main Results:

  • Achieved 100% angiographic success with no procedural complications.
  • Six-month angiographic follow-up in 13 patients showed 8% restenosis and no target vessel revascularization.
  • Long-term follow-up revealed one death (7%) from unrelated CAD progression and one revascularization (7%) for silent ischemia at 24 months.

Conclusions:

  • Intracoronary stenting with Palmaz-Schatz stents appears safe and effective in active duty soldiers with CAD.
  • Preliminary results suggest a significant role for this intervention in managing CAD in this specific demographic.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...